Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B

References

• Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49(Suppl. A): 21–30.
   PubMedGoogle Scholar
• Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect 2008; 14(Suppl. 4): 25–36.
   PubMed Web of Science ®Google Scholar
• Lanternier F, Lortholary O.. Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 2008; 14(Suppl. 4): 71–83.
   PubMedGoogle Scholar
• Cordonnier C, Mohty M, Faucher C, . Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31: 135–141.
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Olson JA, Proffitt RT. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 2004; 54: 1096–1102.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr Opin Infect Dis 2006; 19: 360–364.
   PubMed Web of Science ®Google Scholar
• Olson JA, Adler-Moore JP, Smith PJ, . Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005; 49: 4895–4902.
   PubMed Web of Science ®Google Scholar
• Ortoneda M, Capilla J, Pastor FJ, . Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis 2004; 50:247–251.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R. Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob Agents Chemother 1995; 39: 1885–1887.
   PubMed Web of Science ®Google Scholar
• Shadomy S, McCay JA, Schwartz SI, . Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol 1969; 17: 497–503.
   PubMedGoogle Scholar
• Smith PJ, Olson JA, Constable D, . Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J Antimicrob Chemother 2007; 59: 941–951.
   PubMed Web of Science ®Google Scholar
• Francis P, Lee JW, Hoffman A, . Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infect. J Infect Dis 1994; 169: 356–368.
   PubMed Web of Science ®Google Scholar
• Murphy K, Travers P, Walport M. Chapter 1: Basic Concepts in Immunology. Janeway’s Immunobiology. 7th. New York: Garland Science, 2008.
   Google Scholar
• Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 1980; 186: 591–598.
   PubMed Web of Science ®Google Scholar
• Hirano K, Hunt CA. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J Pharm Sci 1985; 74: 915–921.
   PubMed Web of Science ®Google Scholar
• Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Lip Res 1993; 3: 429–450.
   Google Scholar
• Bekersky I, Fielding RM, Dressler DE, . Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46: 834–840.
   PubMed Web of Science ®Google Scholar
• Abra RM, Hunt CA. Liposome disposition in vivo, III: dose and vesicle-size effects. Biochem. Biophys Acta 1981; 666: 493–503.
   PubMed Web of Science ®Google Scholar
• Groll AH, Lyman CA, Petraitis V, . Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006; 50: 3418–3423.
   PubMed Web of Science ®Google Scholar
• Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45: 922–926.
   PubMed Web of Science ®Google Scholar
• Andes D, Safdar N, Marchillo K, . Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006; 50: 674–684.
   PubMed Web of Science ®Google Scholar
• Goodman JS, Koenig MG. Amphotericin B – specifics of administration. Mod Treat 1970; 7: 581–595.
   PubMedGoogle Scholar
• Olson JA, Adler-Moore JP, Schwartz J, . Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006; 50: 2122–2131.
   PubMed Web of Science ®Google Scholar
• Olson JA, Adler-Moore JP, Jensen GM, . Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother 2008; 52:259–268.
   PubMed Web of Science ®Google Scholar